These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 21386092)

  • 1. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease.
    Capodanno D; Patel A; Dharmashankar K; Ferreiro JL; Ueno M; Kodali M; Tomasello SD; Capranzano P; Seecheran N; Darlington A; Tello-Montoliu A; Desai B; Bass TA; Angiolillo DJ
    Circ Cardiovasc Interv; 2011 Apr; 4(2):180-7. PubMed ID: 21386092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications.
    Spectre G; Arnetz L; Östenson CG; Brismar K; Li N; Hjemdahl P
    Thromb Haemost; 2011 Sep; 106(3):491-9. PubMed ID: 21800009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study.
    Gurbel PA; Bliden KP; DiChiara J; Newcomer J; Weng W; Neerchal NK; Gesheff T; Chaganti SK; Etherington A; Tantry US
    Circulation; 2007 Jun; 115(25):3156-64. PubMed ID: 17562955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study.
    DiChiara J; Bliden KP; Tantry US; Hamed MS; Antonino MJ; Suarez TA; Bailon O; Singla A; Gurbel PA
    Diabetes; 2007 Dec; 56(12):3014-9. PubMed ID: 17848625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease.
    Dillinger JG; Drissa A; Sideris G; Bal dit Sollier C; Voicu S; Manzo Silberman S; Logeart D; Drouet L; Henry P
    Am Heart J; 2012 Oct; 164(4):600-606.e1. PubMed ID: 23067920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy.
    Angiolillo DJ; Bernardo E; Capodanno D; Vivas D; Sabaté M; Ferreiro JL; Ueno M; Jimenez-Quevedo P; Alfonso F; Bass TA; Macaya C; Fernandez-Ortiz A
    J Am Coll Cardiol; 2010 Mar; 55(11):1139-46. PubMed ID: 20223369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.
    Angiolillo DJ; Shoemaker SB; Desai B; Yuan H; Charlton RK; Bernardo E; Zenni MM; Guzman LA; Bass TA; Costa MA
    Circulation; 2007 Feb; 115(6):708-16. PubMed ID: 17261652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of increased aspirin dose versus combined aspirin plus clopidogrel therapy in patients with diabetes mellitus and coronary heart disease and impaired antiplatelet response to low-dose aspirin.
    Duzenli MA; Ozdemir K; Aygul N; Soylu A; Tokac M
    Am J Cardiol; 2008 Aug; 102(4):396-400. PubMed ID: 18678294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration.
    Hedegaard SS; Hvas AM; Grove EL; Refsgaard J; Rocca B; Daví G; Kristensen SD
    Thromb Res; 2009 May; 124(1):96-100. PubMed ID: 19215971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance".
    Santilli F; Rocca B; De Cristofaro R; Lattanzio S; Pietrangelo L; Habib A; Pettinella C; Recchiuti A; Ferrante E; Ciabattoni G; Davì G; Patrono C
    J Am Coll Cardiol; 2009 Feb; 53(8):667-77. PubMed ID: 19232899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced blood platelet sensitivity to aspirin in coronary artery disease: are dyslipidaemia and inflammatory states possible factors predisposing to sub-optimal platelet response to aspirin?
    Markuszewski L; Rosiak M; Golanski J; Rysz J; Spychalska M; Watala C
    Basic Clin Pharmacol Toxicol; 2006 May; 98(5):503-9. PubMed ID: 16635110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study.
    Franchi F; Rollini F; Aggarwal N; Hu J; Kureti M; Durairaj A; Duarte VE; Cho JR; Been L; Zenni MM; Bass TA; Angiolillo DJ
    Circulation; 2016 Sep; 134(11):780-92. PubMed ID: 27559041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Further ex vivo evidence supporting higher aspirin dosing in patients with coronary artery disease and diabetes.
    Bliden KP; Tantry US; DiChiara J; Gurbel PA
    Circ Cardiovasc Interv; 2011 Apr; 4(2):118-20. PubMed ID: 21505165
    [No Abstract]   [Full Text] [Related]  

  • 14. Antiplatelet effect of aspirin in patients with coronary artery disease.
    Grove EL
    Dan Med J; 2012 Sep; 59(9):B4506. PubMed ID: 22951204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease.
    Lordkipanidzé M; Pharand C; Schampaert E; Palisaitis DA; Diodati JG
    Int J Cardiol; 2011 Jul; 150(1):39-44. PubMed ID: 20207433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to low-dose aspirin therapy among patients with acute coronary syndrome in relation to associated risk factors.
    Salama MM; Morad AR; Saleh MA; Sabri NA; Zaki MM; ElSafady LA
    J Clin Pharm Ther; 2012 Dec; 37(6):630-6. PubMed ID: 23121257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease.
    Renda G; Tacconelli S; Capone ML; Sacchetta D; Santarelli F; Sciulli MG; Zimarino M; Grana M; D'Amelio E; Zurro M; Price TS; Patrono C; De Caterina R; Patrignani P
    Clin Pharmacol Ther; 2006 Sep; 80(3):264-74. PubMed ID: 16952493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose- and time-dependent antiplatelet effects of aspirin.
    Perneby C; Wallén NH; Rooney C; Fitzgerald D; Hjemdahl P
    Thromb Haemost; 2006 Apr; 95(4):652-8. PubMed ID: 16601836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced antiplatelet effect of aspirin during 24 hours in patients with coronary artery disease and type 2 diabetes.
    Christensen KH; Grove EL; Würtz M; Kristensen SD; Hvas AM
    Platelets; 2015; 26(3):230-5. PubMed ID: 24750015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study.
    Angiolillo DJ; Bernardo E; Palazuelos J; Desai B; Weisberg I; Alfonso F; Guzman LA; Hernández-Antolin R; Zenni MZ; Macaya C; Fernandez-Ortiz A; Bass TA
    Thromb Haemost; 2008 Jan; 99(1):161-8. PubMed ID: 18217149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.